Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
33%(1 trials)

Phase Distribution

Ph phase_2
1
25%
Ph phase_4
1
25%
Ph not_applicable
1
25%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Other(1)

Detailed Status

Completed3
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (33.3%)
Phase 41 (33.3%)
N/A1 (33.3%)

Trials by Status

unknown125%
completed375%

Recent Activity

0 active trials
Showing 4 of 4
completed

Evaluation of Somatostatin Receptors and GH Receptor Expression on Bone of Acromegalic Patients (ACRO-BONE)

NCT05819554
completednot_applicable

Transsphenoidal Extent of Resection Study

NCT02357498
completedphase_4

Surgical Debulking of Pituitary Adenomas

NCT01371643
unknownphase_2

Preoperative Lanreotide Treatment in Acromegalic Patients With Macroadenomas

NCT00993356

Clinical Trials (4)

Showing 4 of 4 trials
NCT05819554

Evaluation of Somatostatin Receptors and GH Receptor Expression on Bone of Acromegalic Patients (ACRO-BONE)

Completed
NCT02357498Not Applicable

Transsphenoidal Extent of Resection Study

Completed
NCT01371643Phase 4

Surgical Debulking of Pituitary Adenomas

Completed
NCT00993356Phase 2

Preoperative Lanreotide Treatment in Acromegalic Patients With Macroadenomas

Unknown

All 4 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
4